Donald E. Hricik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Donald E. Hricik has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
J A Schulak
8 shared publicationsJames A. Schulak
5 shared publicationsChristopher Siegel
3 shared publicationsJ T Mayes
3 shared publicationsThomas C. Knauss
3 shared publicationsVictoria Rodriguez
3 shared publications
Latest Publications
- 1 February 2007
- Published by Wolters Kluwer Health in Transplantation
- Vol. 83 (3) , 277-281
Long-Term Graft Outcomes After Steroid Withdrawal in African American Kidney Transplant Recipients Receiving Sirolimus and Tacrolimus
We previously reported excellent short-term outcomes in African American kidney transplant patients receiving tacrolimus/sirolimus and withdrawn from corticosteroid therapy three months after transplantation. We now report the long-term outcomes of patients subjected to this protocol. In all, 47 African American kidney transplant recipients were enrolled in an uncontrolled trial in which they were initially treated with sirolimus, tacrolimus, and corticosteroids, without antibody induction therapy. Eligible patients were withdrawn from prednisone between three and five months posttransplant, and followed for acute rejection and changes in renal function. Outcomes (group 1, n=32) were compared to those of patients deemed not to be candidates for steroid withdrawal (group 2, n=15). After a mean follow-up of 48.5 months, 13 of 32 patients (41%) in group 1 developed acute rejection; only 13 patients (41%) remain steroid-free. Nine of 13 rejection episodes were associated with noncompliance. Graft loss occurred in 8 of 32 patients (25%) in group 1 and in 5 of 15 patients (33%) in group 2 (P=NS). Serum creatinine rose from 1.4+/-0.41 to 2.45+/-1.7 mg/dL in group 1 (P=0.004) and from 2.1+/-0.45 to 2.62+/-1.2 mg/dL (P=NS) in group 2. Among 13 patients in group 1 who remain steroid-free, creatinine concentration has risen from 1.28+/-.0.37 prior to steroid withdrawal to 1.64+0.54 at last follow-up (P=0.027). Late noncompliance and/or rejection in African Americans withdrawn from steroids have a negative impact on long-term graft function and survival. Steroid withdrawal may be associated with long-term deterioration of renal function, even in the absence of overt acute rejection.
- 1 February 2007
- Published by Wolters Kluwer Health in Transplantation
- Vol. 83 (3) , 277-281
Long-Term Graft Outcomes After Steroid Withdrawal in African American Kidney Transplant Recipients Receiving Sirolimus and Tacrolimus
We previously reported excellent short-term outcomes in African American kidney transplant patients receiving tacrolimus/sirolimus and withdrawn from corticosteroid therapy three months after transplantation. We now report the long-term outcomes of patients subjected to this protocol. In all, 47 African American kidney transplant recipients were enrolled in an uncontrolled trial in which they were initially treated with sirolimus, tacrolimus, and corticosteroids, without antibody induction therapy. Eligible patients were withdrawn from prednisone between three and five months posttransplant, and followed for acute rejection and changes in renal function. Outcomes (group 1, n=32) were compared to those of patients deemed not to be candidates for steroid withdrawal (group 2, n=15). After a mean follow-up of 48.5 months, 13 of 32 patients (41%) in group 1 developed acute rejection; only 13 patients (41%) remain steroid-free. Nine of 13 rejection episodes were associated with noncompliance. Graft loss occurred in 8 of 32 patients (25%) in group 1 and in 5 of 15 patients (33%) in group 2 (P=NS). Serum creatinine rose from 1.4+/-0.41 to 2.45+/-1.7 mg/dL in group 1 (P=0.004) and from 2.1+/-0.45 to 2.62+/-1.2 mg/dL (P=NS) in group 2. Among 13 patients in group 1 who remain steroid-free, creatinine concentration has risen from 1.28+/-.0.37 prior to steroid withdrawal to 1.64+0.54 at last follow-up (P=0.027). Late noncompliance and/or rejection in African Americans withdrawn from steroids have a negative impact on long-term graft function and survival. Steroid withdrawal may be associated with long-term deterioration of renal function, even in the absence of overt acute rejection.
- Open Access
- 1 April 2005
- Published by Elsevier in American Journal of Transplantation
- Vol. 5 (4) , 639-640
Steroid Withdrawal for the (Selected) Masses
- 1 April 2005
- Published by Elsevier in American Journal of Transplantation
- Vol. 5 (4) , 639-640
Open AccessSteroid Withdrawal for the (Selected) Masses
- 1 September 2003
- Published by Wolters Kluwer Health in Transplantation
- Vol. 76 (6) , 938-942
Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus.1
Withdrawal of corticosteroids from the immunosuppressive regimens of kidney transplant recipients has been associated with an increased risk of acute and chronic allograft rejection. Previous studies indicate that the risk of rejection is particularly high in African Americans. We prospectively enrolled 44 African American kidney transplant recipients to participate in an uncontrolled trial in which they were initially treated with sirolimus, tacrolimus, and corticosteroids. No patient received antibody induction therapy. Prednisone was withdrawn from eligible patients free of acute rejection beginning as early as 3 months posttransplant, and followed for a minimum of 9 months posttransplant. Patients were followed for acute rejection and for changes in blood pressure, body weight, and serum creatinine concentrations before and after withdrawal of steroids. Thirty of 44 patients (68%) were weaned off of prednisone. Follow-up after withdrawal of prednisone ranged from 3 to 26 months (mean, 14.3+/-7.7 months). Two of 30 patients (6.7%) developed acute rejection. At last follow-up, 27 of 30 patients (90%) remain steroid-free. Steroid withdrawal was associated with significant reductions in blood pressure. Use of sirolimus and tacrolimus, without the use of induction antibody therapy, allows withdrawal of prednisone as early as 3 months posttransplant with low rates of subsequent acute rejection in African American kidney transplant recipients. Withdrawal of prednisone was associated with lower blood pressures and the need for fewer antihypertensive medications.
- 1 September 2003
- Published by Wolters Kluwer Health in Transplantation
- Vol. 76 (6) , 938-942
Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus.1
Withdrawal of corticosteroids from the immunosuppressive regimens of kidney transplant recipients has been associated with an increased risk of acute and chronic allograft rejection. Previous studies indicate that the risk of rejection is particularly high in African Americans. We prospectively enrolled 44 African American kidney transplant recipients to participate in an uncontrolled trial in which they were initially treated with sirolimus, tacrolimus, and corticosteroids. No patient received antibody induction therapy. Prednisone was withdrawn from eligible patients free of acute rejection beginning as early as 3 months posttransplant, and followed for a minimum of 9 months posttransplant. Patients were followed for acute rejection and for changes in blood pressure, body weight, and serum creatinine concentrations before and after withdrawal of steroids. Thirty of 44 patients (68%) were weaned off of prednisone. Follow-up after withdrawal of prednisone ranged from 3 to 26 months (mean, 14.3+/-7.7 months). Two of 30 patients (6.7%) developed acute rejection. At last follow-up, 27 of 30 patients (90%) remain steroid-free. Steroid withdrawal was associated with significant reductions in blood pressure. Use of sirolimus and tacrolimus, without the use of induction antibody therapy, allows withdrawal of prednisone as early as 3 months posttransplant with low rates of subsequent acute rejection in African American kidney transplant recipients. Withdrawal of prednisone was associated with lower blood pressures and the need for fewer antihypertensive medications.
- Open Access
- 1 July 2003
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (7) , 771-772
… Life Lies Waiting
Click on the article title to read more.
- 1 July 2003
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (7) , 771-772
Open Access… Life Lies Waiting
Click on the article title to read more.
- Open Access
- 1 July 2003
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (7) , 878-884
Enzyme Linked Immunosorbent Spot (ELISPOT) Assay for Interferon‐Gamma Independently Predicts Renal Function in Kidney Transplant Recipients
Post-transplant monitoring of cellular immunity might be useful in predicting long-term outcomes of kidney transplant recipients. We used an enzyme linked immunoabsorbent spot (ELISPOT) assay to ser...
- 1 July 2003
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (7) , 878-884
Open AccessEnzyme Linked Immunosorbent Spot (ELISPOT) Assay for Interferon‐Gamma Independently Predicts Renal Function in Kidney Transplant Recipients
Post-transplant monitoring of cellular immunity might be useful in predicting long-term outcomes of kidney transplant recipients. We used an enzyme linked immunoabsorbent spot (ELISPOT) assay to ser...
- 6 May 2003
- Published by Elsevier in Transplantation Proceedings
- Vol. 35 (3) , S73-S78
Use of sirolimus to facilitate cyclosporine avoidance or steroid withdrawal in kidney transplant recipients
- 6 May 2003
- Published by Elsevier in Transplantation Proceedings
- Vol. 35 (3) , S73-S78
Use of sirolimus to facilitate cyclosporine avoidance or steroid withdrawal in kidney transplant recipients
- 1 July 2002
- Published by Wolters Kluwer Health in Transplantation
- Vol. 74 (2) , 189-193
Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids
African American kidney transplant recipients generally exhibit poor long-term graft survival compared with other ethnic groups. The combination of sirolimus, tacrolimus, and corticosteroids has proven to be effective in reducing rejection episodes in high-risk organ and islet cell transplant recipients but has not yet been tested in a large number of African American patients. The outcomes of 56 African American adult, primary kidney transplant recipients treated with corticosteroids, sirolimus, and tacrolimus targeted to relatively low trough blood levels were compared with those of a concurrent group of 65 white patients treated with steroids, mycophenolate mofetil, and tacrolimus targeted to relatively high blood levels. Induction antibody therapy was not routinely used in either group. The incidence of acute rejection in the first 3 posttransplantation months was 7.1% in African Americans and 16.9% in whites (P =NS). Actuarial 2-year patient, graft, and rejection-free graft survival rates were equivalent in the two groups. Posttransplantation diabetes mellitus occurred in 36% of the African American patients, despite similar doses of corticosteroids and lower trough levels of tacrolimus, compared with 15% of white patients (P =0.024). The combination of corticosteroids, sirolimus, and relatively low doses of tacrolimus results in acute rejection, graft survival, and patient survival rates equivalent to those achieved in white patients receiving steroids, mycophenolate mofetil, and relatively high doses of tacrolimus, even without the routine use of induction antibody therapy. Posttransplantation diabetes mellitus remains a problem for African Americans receiving this combination of immunosuppressants, despite relatively low tacrolimus blood levels.
- 1 July 2002
- Published by Wolters Kluwer Health in Transplantation
- Vol. 74 (2) , 189-193
Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids
African American kidney transplant recipients generally exhibit poor long-term graft survival compared with other ethnic groups. The combination of sirolimus, tacrolimus, and corticosteroids has proven to be effective in reducing rejection episodes in high-risk organ and islet cell transplant recipients but has not yet been tested in a large number of African American patients. The outcomes of 56 African American adult, primary kidney transplant recipients treated with corticosteroids, sirolimus, and tacrolimus targeted to relatively low trough blood levels were compared with those of a concurrent group of 65 white patients treated with steroids, mycophenolate mofetil, and tacrolimus targeted to relatively high blood levels. Induction antibody therapy was not routinely used in either group. The incidence of acute rejection in the first 3 posttransplantation months was 7.1% in African Americans and 16.9% in whites (P =NS). Actuarial 2-year patient, graft, and rejection-free graft survival rates were equivalent in the two groups. Posttransplantation diabetes mellitus occurred in 36% of the African American patients, despite similar doses of corticosteroids and lower trough levels of tacrolimus, compared with 15% of white patients (P =0.024). The combination of corticosteroids, sirolimus, and relatively low doses of tacrolimus results in acute rejection, graft survival, and patient survival rates equivalent to those achieved in white patients receiving steroids, mycophenolate mofetil, and relatively high doses of tacrolimus, even without the routine use of induction antibody therapy. Posttransplantation diabetes mellitus remains a problem for African Americans receiving this combination of immunosuppressants, despite relatively low tacrolimus blood levels.
- Open Access
- 1 January 2002
- Published by Elsevier in American Journal of Transplantation
- Vol. 2 (1) , 19-24
Steroid-free Immunosuppression in Kidney Transplantation: An Editorial Review
Click on the article title to read more.
- 1 January 2002
- Published by Elsevier in American Journal of Transplantation
- Vol. 2 (1) , 19-24
Open AccessSteroid-free Immunosuppression in Kidney Transplantation: An Editorial Review
Click on the article title to read more.
- 27 October 2001
- Vol. 72, S32-5
Minimization of immunosuppression in kidney transplantation. The need for immune monitoring.
- 27 October 2001
- Vol. 72, S32-5
Minimization of immunosuppression in kidney transplantation. The need for immune monitoring.